| Prakash Seshadri, MD | |
|
3506 Kennett Pike, Cchs Diabetes And Metabolic Disease Center, Wilmington, DE 19807-3019 | |
| (302) 661-3070 | |
| (302) 661-3080 |
| Full Name | Prakash Seshadri |
|---|---|
| Gender | Male |
| Speciality | Endocrinology |
| Experience | 21 Years |
| Location | 3506 Kennett Pike, Wilmington, Delaware |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134144330 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | C10008054 (Delaware) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Christiana Hospital | Newark, DE | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Christiana Care Health Services Inc | 9739097569 | 1248 |
News Archive
An international team of researchers led by clinicians at Weill Cornell Medical College have discovered a genetic Achilles' heel in an aggressive type of prostate cancer - a vulnerability they say can be attacked by a targeted drug that is already in clinical trials to treat other types of cancers.
Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today the signing of an exclusive worldwide licensing agreement for the development and co-commercialization of MM-121, a first-in-class, fully human monoclonal antibody designed to block signaling of the ErbB3 receptor. MM-121 is currently in Phase 1 clinical testing.
Researchers report a method of removing noise from high-resolution transmission electron microscopy images using probabilistic generative models.
In Ontario, an astounding 1.7 million people have asthma, making it one of the most widespread chronic diseases. Nearly half of them don't have it under control and yet asthma is a disease that must be well managed because there is no cure.
› Verified 3 days ago
| Entity Name | Christiana Care Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770568107 PECOS PAC ID: 9739097569 Enrollment ID: O20031201000477 |
News Archive
An international team of researchers led by clinicians at Weill Cornell Medical College have discovered a genetic Achilles' heel in an aggressive type of prostate cancer - a vulnerability they say can be attacked by a targeted drug that is already in clinical trials to treat other types of cancers.
Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today the signing of an exclusive worldwide licensing agreement for the development and co-commercialization of MM-121, a first-in-class, fully human monoclonal antibody designed to block signaling of the ErbB3 receptor. MM-121 is currently in Phase 1 clinical testing.
Researchers report a method of removing noise from high-resolution transmission electron microscopy images using probabilistic generative models.
In Ontario, an astounding 1.7 million people have asthma, making it one of the most widespread chronic diseases. Nearly half of them don't have it under control and yet asthma is a disease that must be well managed because there is no cure.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Prakash Seshadri, MD 3506 Kennett Pike, Pmri, Wilmington, DE 19807-3019 Ph: (302) 661-3070 | Prakash Seshadri, MD 3506 Kennett Pike, Cchs Diabetes And Metabolic Disease Center, Wilmington, DE 19807-3019 Ph: (302) 661-3070 |
News Archive
An international team of researchers led by clinicians at Weill Cornell Medical College have discovered a genetic Achilles' heel in an aggressive type of prostate cancer - a vulnerability they say can be attacked by a targeted drug that is already in clinical trials to treat other types of cancers.
Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today the signing of an exclusive worldwide licensing agreement for the development and co-commercialization of MM-121, a first-in-class, fully human monoclonal antibody designed to block signaling of the ErbB3 receptor. MM-121 is currently in Phase 1 clinical testing.
Researchers report a method of removing noise from high-resolution transmission electron microscopy images using probabilistic generative models.
In Ontario, an astounding 1.7 million people have asthma, making it one of the most widespread chronic diseases. Nearly half of them don't have it under control and yet asthma is a disease that must be well managed because there is no cure.
› Verified 3 days ago
Dr. Shady Abdelbaki, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 501 W 14th St, Wilmington, DE 19801 Phone: 302-320-2490 Fax: 302-623-4395 | |
Terry L Horton, MD Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 501 W 14th St, Room 5236, Wilmington, DE 19801 Phone: 302-428-4574 Fax: 302-428-2569 | |
Dr. Susan M Keith, MD Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 1601 Kirkwood Hwy, Wilmington, DE 19805 Phone: 302-633-5302 Fax: 302-633-5582 | |
Dr. Melissa D. Morgan-gouveia, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 501 W 14th St, Wilmington Hospital - Adult Medicine Office, Wilmington, DE 19801 Phone: 302-428-4411 Fax: 302-428-4667 | |
Dr. Alfonso Paul Ciarlo, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 5311 Limestone Road, Suite 100, Wilmington, DE 19808 Phone: 302-234-2200 Fax: 302-234-2262 | |
Dr. Robert Anselmo Jakubowski, M.D. Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 501 W 14th St Fl 6, Wilmington, DE 19801 Phone: 302-320-1300 Fax: 302-320-1373 | |
Dr. Brajesh Narayan Agarwal, M.D. Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 1601 Kirkwood Hwy, Medical Service (111), Wilmington, DE 19805 Phone: 302-633-5302 Fax: 302-633-5582 |